Table 1.

Comparison of 14 Subjects With Post-Treatment Lyme Disease Symptoms vs 114 Without

Variable	Patients Without Evidence of Post-Treatment Lyme Disease Symptoms	Patients With Possible Post-Treatment Lyme Disease Symptoms	P Value
No.	114	14
No. males	64 (56.1)	7 (50.0)	.78
Age at baseline visit in years ± SD (range)	48.27 ± 11.71 (25–76)	51 ± 10.44 (37–72)	.41
Mean no. of days of illness until baseline visit ± SD (range)	5.82 ± 7.33 (0–42)	4.29 ± 5.01 (0–16)	.45
Single EM at baseline	95 (83.3)	8 (57.1)	.03
Symptomatic at study entry	91 (79.8)	13 (92.9)	.47
Mean no. of symptoms ± SD at baseline visit (range)	3.28 ± 2.84 (0–10)	4.64 ± 2.56 (0–9)	.09
History of Lyme	22 (19.3)	1 (7.1)	.46
Intercurrent EM	27 (23.7)	2 (14.3)	.74
Antibiotics active against Lymea	93 (81.6)	12 (85.7)	1.00
Lyme serologies consistently negativeb	20 (17.5)	1 (7.1)	.46
≥50% of the Lyme serologies performed were reactiveb,c	49 (43.0)	8 (57.1)	.40
No. with reactive Lyme serology at the baseline visitc	43 (44.3) (out of n = 97)	7 (53.9) (out of n = 13)	.56
Number with reactive Lyme serology at final visitc	49 (43.0)	4 (30.8) (out of n = 13)	.56
Mean no. of visits ± SD (range)	13.77 ± 3.76 (5–22)	13.57 ± 3.48 (8–19)	.85
Mean duration of visits ± SD (range), y	14.94 ± 2.70 (11–20)	15.29 ± 2.89 (11–20)	.65
FSS-11 score at last visit (range)	2.02 ± 1.27 (1–7) (out of n = 88)	2.22 ± 1.61 (1–6.7) (out of n = 12)	.62
Intercurrent comorbidity	81 (71.1)	8 (57.1)	.36
Intercurrent hospitalizations	54 (47.4)	8 (57.1)	.58

Data are no. (%) unless otherwise noted.

Abbreviations: EM, erythema migrans; FSS-11, Fatigue Severity Scale 11; SD, standard deviation.

^a Antibiotics prescribed for reasons other than Lyme disease.

^b Serologic testing was performed with blood samples obtained at each follow-up visit.

^c Reactive serology indicates that a first-tier serologic test was positive or equivocal.